Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171161 | 0.89 | CYP19A1 (0.58) | CYP19A1CYP11B1CYP11B2TBXAS1KMT2A | |
| SCHEMBL3547546 | 0.70 | HRH3 (0.38) | HRH3CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL5041356 | 0.70 | NPC1 (0.46) | — | |
| Hydrochloric Acid SCHEMBL3553023 | 0.69 | HRH3 (0.37) | HRH3CYP19A1TBXAS1KMT2AMEN1 | |
| SCHEMBL1170919 | 0.67 | ALOX15 (0.39) | KMT2AMEN1 | |
| SCHEMBL1171095 | 0.67 | HTR1A (0.38) | HRH3SMN1; SMN2 | |
| SCHEMBL5456305 | 0.64 | TBXAS1 (0.46) | CYP19A1TBXAS1KMT2A | |
| SCHEMBL1552675 | 0.63 | CYP19A1 (1.00) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL570591 | 0.62 | CYP11B1 (0.66) | CYP19A1CYP11B1TBXAS1KMT2A | |
| SCHEMBL15179017 | 0.62 | CYP19A1 (0.64) | CYP19A1CYP11B1CYP11B2TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | HRH3 1012/4885CYP19A1 834/4885CYP11B1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.